# Base Editing **Entity class:** Method **Domain:** Genome Editing / Personalized Therapeutics **Doc Type:** Technology Node **Maturity:** Human-translational **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences|Research Inferences]] (INF-0331) ## Definition **Base editing changes a single nucleotide in place, without cutting both strands of the DNA.** A deaminase enzyme fused to a targeting protein converts one base to another at a specified position, which addresses the largest class of pathogenic variants: single-letter changes. Roughly 350 million people live with one of about 5,000 genetic diseases, many carrying mutations unique to an individual, and that population defines the addressable market of individualized editing. ## Clinical record - **[[wiki/Baby KJ|Baby KJ]] (February and March 2025).** An infant with severe CPS1 deficiency received a base editor bound to a bespoke guide, delivered by [[wiki/Lipid Nanoparticle|lipid nanoparticle]] at seven and eight months old; the first personalized in vivo editing therapy in a human. - **Duchenne muscular dystrophy.** Base-editing treatment has maintained broadly stable motor function at one year in treated boys, and in vivo exon-targeting programs have entered clinical testing. - **Accelerated approval.** Alignment with the FDA on biomarker-based accelerated approval for a base-editing therapy shortens the evidence timeline for the whole modality. - **Risk boundary.** A death following experimental base editing for a nonfatal neurodevelopmental disorder in China in 2026 marks the boundary between acceptable and unacceptable risk in indications that are not life-threatening. - **Designed enzymes.** AI-engineered base editors are distributed through access programs, which makes the editing enzyme a designed object rather than a discovered one. ## Forward Capability When the enzyme is designed, the guide is a string and delivery is a formulation, the therapeutic becomes a computationally specified artifact and its iteration loop starts to resemble software. The register's reading is that regulatory throughput, not editing chemistry, was the binding constraint; the [[wiki/Plausible Mechanism Framework|Plausible Mechanism Framework]] relaxes it directly. Combined with redosable delivery, the genome becomes a maintainable system rather than a fixed inheritance. ## Open Questions - Off-target assessment depth as sequencing cost falls, and what that quietly expands in approvability. - Manufacturing analytics when each patient's dose is its own production run. - Whether maintenance editing of accumulated somatic damage becomes a longevity indication. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0331 — Established.** Base editors change single nucleotides without breaks, addressing the largest class of pathogenic variants. Roughly 350 million people live with one of about 5,000 genetic diseases, many carrying mutations unique to an individual, which defines the addressable population of individualized editing. - **INF-0326 — Established.** An infant with CPS1 deficiency received a bespoke base-editing therapy designed for his individual mutation, dosed in February 2025 — the first personalized in vivo gene-editing treatment in a human. The unit of therapy became one patient, which is a structural break with every prior drug development model. - **INF-0340 — Established.** Base-editing treatment of Duchenne muscular dystrophy has maintained broadly stable motor function at one year in treated boys, and in vivo exon-targeting programs have entered clinical testing. Durable functional benefit from a single in vivo edit is now observed rather than projected. - **INF-0341 — Established.** Alignment with the FDA on biomarker-based accelerated approval for a base-editing therapy shortens the evidence timeline for the whole modality. Biomarker endpoints are how a slow-moving disease becomes a fast-moving clinical program. - **INF-0335 — Plausible.** If an edit can be delivered repeatedly and safely, the genome becomes a maintainable system rather than a fixed inheritance. Periodic correction of accumulated somatic damage is the logical endpoint, and it is an extension of an established delivery route rather than a new modality. - **INF-0346 — Analytic.** When the enzyme is designed, the guide is a string, and delivery is a formulation, the whole therapeutic becomes a computationally specified artifact. The iteration loop for medicine begins to resemble the iteration loop for software, which changes its improvement rate. ## Relationships - **technique_peer:** [[wiki/Prime Editing|Prime Editing]] (writes specified sequences rather than converting single bases). - **delivery:** [[wiki/Lipid Nanoparticle|Lipid Nanoparticle]]. - **first_personalized_case:** [[wiki/Baby KJ|Baby KJ]]. - **regulatory_vehicle:** [[wiki/Plausible Mechanism Framework|Plausible Mechanism Framework]] · [[wiki/United States Food and Drug Administration|United States Food and Drug Administration]]. - **funder:** [[wiki/ARPA-H|ARPA-H]] (AEGIS consortium for personalized in vivo editing). - **cluster_home:** [[wiki/Real-Time Genetic Repair|Real-Time Genetic Repair]]. - **CNS_frontier:** [[wiki/Molecular Neural Interfaces|Molecular Neural Interfaces]] · [[wiki/Intranasal CNS Delivery|Intranasal CNS Delivery]]. - **ecosystem:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[collections/Neurotech|Neurotech]]. ## Sources - [Patient-specific in vivo gene editing to treat a rare genetic disease — New England Journal of Medicine, 15 May 2025](https://doi.org/10.1056/NEJMoa2504747) - [First human study shows potential of personalized gene editing treatments — NIH Common Fund](https://commonfund.nih.gov/news/first-human-study-shows-potential-personalized-gene-editing-treatments-wide-range-disorders) - [Considerations for the Use of the Plausible Mechanism Framework — Federal Register, 25 February 2026](https://www.federalregister.gov/documents/2026/02/25/2026-03713/considerations-for-the-use-of-the-plausible-mechanism-framework-to-develop-individualized-therapies) As of 23 October 2026.